| Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners |
2021-10-14 |
| Rectify Pharmaceuticals–Forbion: investment, 202110 financing round Series A totalling $100m incl co-lead investor Forbion |
2021-10-14 |
| Rectify Pharmaceuticals–SEVERAL: investment, 202110 financing round Series A $100m co-led by Atlas Venture + Omega Funds + Forbion + Longwood Fund |
2021-10-14 |
| VeroVaccines–SEVERAL: investment, 202110 financing round Series B mid-7-figure € from consortium of investors from Germany + Switzerland |
2021-10-14 |
| SparingVision–Intellia Therapeutics: CRISPR technology, 202110– collab incl license to use CRISPR/Cas9 to develop genomic ocular disease treatments |
2021-10-13 |
| SparingVision–Intellia Therapeutics: investment, 202110 Intellia receives 10% equity ownership in SparingVision as part of collab/license agreem |
2021-10-13 |
| ISD Immunotech–Eir Ventures: investment, 202110 investment by new investor Eir Ventures |
2021-10-11 |
| ISD Immunotech–Novo Group: investment, 202110 existent lead investor Novo Seeds |
2021-10-11 |
| Autolomous–Image Box: public relations, 202110 service existent by Image Box Communications |
2021-10-08 |
| Bico–SEVERAL: investment, 202110 direct share issue SEK2.04b ($232m) with 4.25m Series B Shares at SEK480/share (= 5.6% discount) |
2021-10-07 |
| Creapaper–eCapital: investment, 202110 financing round Series B totalling €20m incl existing investor eCapital |
2021-10-06 |
| Creapaper–EU (govt): investment, 202110 financing round Series B totalling €20m incl new investor EIC Fund |
2021-10-06 |
| Creapaper–JS Capital: investment, 202110 financing round Series B totalling €20m incl new investor JS Capital |
2021-10-06 |
| Creapaper–Ranpak: investment, 202110 financing round Series B totalling €20m incl new investor Ranpak |
2021-10-06 |
| Creapaper–Schusterman Family Investments: investment, 202110 financing round Series B totalling €20m incl new investor Schusterman Family Investments |
2021-10-06 |
| Creapaper–SEVERAL: investment, 202110 financing round Series B €20m |
2021-10-06 |
| Creapaper–Soros Capital: investment, 202110 financing round Series B totalling €20m incl new investor Soros Capital |
2021-10-06 |
| Atbtherapeutics–Trophic Communications: public relations, 202110 service existent by Trophic Communications |
2021-10-05 |
| Cellecta–Merck (DE): CRISPR technology, 202110– license for CRISPR-Cas9 technology to Cellecta |
2021-10-05 |
| Exo Therapeutics–SEVERAL: investment, 202120 financing round Series B $78m lead by new investor Nextech invest |
2021-10-05 |
| iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG |
2021-10-05 |
| Synklino–Denmark (govt): investment, 202110– financing round targeting DKK35m incl existing + co-lead investor Vaekstfonden Venture |
2021-10-05 |
| Synklino–Eir Ventures: investment, 202110– financing round targeting DKK35m incl existing + co-lead investor Eir Ventures |
2021-10-05 |
| Synklino–SEVERAL: investment, 202110– financing round targeting DKK35m co-led by Eir Ventures + Vaekstfonden Venture |
2021-10-05 |
| Pierre Fabre–Atara Biotherapeutics: tabelecleucel, 202110– collab $45m upfront + $320m milestones + royalties excl sales in EMEA for EBV+ cancers |
2021-10-04 |
| Genetic Analysis (NO)–SEVERAL: investment, 202110 IPO at Swedish Spotlight Stock Market raising $6.8m |
2021-10-03 |
| QInstruments–Bico: investment, 202110– acquisition 100% cash/debt free for €58.25m upfront + €3m milestones thereof 13% paid in new Bico shares |
2021-10-01 |
| Aglaia Therapeutics–Advent France Biotechnology: investment, 202109 seed financing round totalling €4m incl co-founder + lead investor AFB |
2021-09-27 |
| Aglaia Therapeutics–Crédit Mutuel-CIC: investment, 202109 seed financing round totalling €4m incl co-investor Crédit Mutuel Innovation |
2021-09-27 |
| Aglaia Therapeutics–Pierre Fabre: investment, 202109 seed financing round totalling €4m incl co-investor Pierre Fabre |
2021-09-27 |
| Aglaia Therapeutics–SEVERAL: investment, 202109 seed financing round €4m led by Advent FB with Crédit Mutuel Innovation + Pierre Fabre |
2021-09-27 |
| Panakès Partners–Huntsworth: public relations, 202109 service existent by Medistrava Consulting |
2021-09-27 |
| AstraZeneca–VaxEquity: saRNA technology, 202109– collab up to $195m + royalties for up to 26 drug targets |
2021-09-23 |
| Thermo Fisher–Carbon Engineering: analytical technology, 202109 collab existent direct air capture technology to reduce CO2 emissions |
2021-09-23 |
| VaxEquity–AstraZeneca: investment, 202109 equity investment by AstraZeneca in connection with strategic research collab |
2021-09-23 |
| VaxEquity–Morningside: investment, 202109 equity investment by Morningside Ventures |
2021-09-23 |
| VaxEquity–Scius Communications: public relations, 202109 supply service existent by Scius Communications |
2021-09-23 |
| Univ Aarhus–Novo Group: grant, 202109–202808 grant DKK630m (€84.7m) to establish NNF CO2 Research Center at AU + six satellite institutes |
2021-09-22 |
| Accession Therapeutics–Birk Venture: investment, 202109 1st tranche of long-term funding round incl Birk Venture |
2021-09-20 |
| Accession Therapeutics–Primavera Capital: investment, 202109 1st tranche of long-term funding round incl Primavera Venture Partners |
2021-09-20 |
| Accession Therapeutics–SEVERAL: investment, 202109 1st tranche of long-term funding round incl Primavera Venture Partners + Birk Venture |
2021-09-20 |
| Intrance–PERSON: investment, 202109 investment $8m by Erik Selin Fastigheter AB as anchor investor of $15m Series A round of Intrance Medical Systems |
2021-09-20 |
| Jeito Capital–SEVERAL: investment, 202109 final closing Jeito I with addit €284m at €534m after €200m 1st close + €50m from Sanofi |
2021-09-20 |
| Biotest–Grifols: investment, 202109– public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share |
2021-09-17 |
| Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash |
2021-09-17 |
| Anjarium Biosciences–Abingworth: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Abingworth |
2021-09-16 |
| Anjarium Biosciences–Citadel: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Surveyor Capital |
2021-09-16 |
| Anjarium Biosciences–Gimv: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Gimv |
2021-09-16 |
| Anjarium Biosciences–Huntsworth: public relations, 202109 service existent by Medistrava Consulting |
2021-09-16 |
| Anjarium Biosciences–Omega Funds: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Omega Funds |
2021-09-16 |
| Anjarium Biosciences–Pfizer: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Pfizer Ventures |
2021-09-16 |
| Anjarium Biosciences–SEVERAL: investment, 202109 financing round Series A CHF55.5m ($61m) co-led by Abingworth + Gimv |
2021-09-16 |
| BRAIN Biotech–SEVERAL: investment, 202109 capital increase €19.6m with 1.99m new shares at €9.85/share to institutional investors |
2021-09-15 |
| Clean Biologics–Andrew Lloyd Associates: public relations, 202109 service existent for Clean Cells by ALA |
2021-09-15 |
| Clean Biologics–ArchiMed: investment, 202109 investment existent by ArchiMed |
2021-09-15 |
| Hurel–Bico: investment, 202109 acquisition $2.5m of assets + operations of Hurel Corp + integration in Visikol |
2021-09-15 |
| Touchlight–Bridford Group: investment, 202109 financing round extension £50m incl co-lead investor Bridford Investments Ltd |
2021-09-15 |
| Touchlight–Novator Partners: investment, 202109 financing round extension £50m incl co-lead investor Novator Partners |
2021-09-15 |
| Touchlight–SEVERAL: investment, 202109 financing round extension £50m bringing total round to £92m led by Bridford + Novator |
2021-09-15 |
| Evotec–Biognosys: MS-based proteomics, 202109– collab integration of Spectronaut proteomics data analys into drug discovery + clinical proteomics |
2021-09-14 |
| Meatable–DSM: cell culture media, 202109– collab developm growth media for cultivated meat |
2021-09-13 |
| TreeFrog Therapeutics–BMS: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor BMS |
2021-09-13 |
| TreeFrog Therapeutics–France (govt): investment, 202109 financing round Series B totalling $75m (€64m) incl lead investor Bpifrance Large Venture |
2021-09-13 |
| TreeFrog Therapeutics–Leonard Green: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor Leonard Green + Partners LP |
2021-09-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 202109 financing round Series B $75m (€64m) led by Bpifrance Large Venture |
2021-09-13 |
| TreeFrog Therapeutics–Siparex: investment, 202109 financing round Series B totalling $75m (€64m) incl exisiting + co-investor XAnge |
2021-09-13 |
| Genedrive–SEVERAL: investment, 202109– capital increase open offer up to £4.5m with up to 18.1m shares at 25p/share w 40.1% discount ANNOUNCED |
2021-09-10 |
| Genedrive–SEVERAL: investment, 202109–202110 capital increase placing £6m (net £5.6m) with 24m new ordinary shares at 25p/share w 40.1% discount |
2021-09-10 |
| Genedrive–Walbrook PR: public relations, 202109 service existent by Walbrook PR |
2021-09-10 |
| Boehringer–Twist Bioscience: antibody drug discovery, 202109– collab using Twist Biopharma antibody phage display libraries against Boehringer targets |
2021-09-09 |
| TIB Molbiol–Roche: investment, 202109– acquisition 100% of TIB Mobiol Group by Roche SIGNED |
2021-09-09 |
| EnteroBiotix–Kineticos Life Sciences: investment, 202109 financing round Series A totalling £15.5m incl new + co-investor KIneticos Ventures |
2021-09-07 |
| EnteroBiotix–Scius Communications: public relations, 202109 supply service existent by Scius Communications |
2021-09-07 |
| EnteroBiotix–Scotland (govt): investment, 202109 financing round Series A totalling £15.5m incl existing + co-investor Scottish Enterprise |
2021-09-07 |
| EnteroBiotix–SEVERAL: investment, 202109 financing round Series A £15.5m ($21.5m) led by Thairm Bio |
2021-09-07 |
| EnteroBiotix–Social Investment Scotland: investment, 202109 financing round Series A totalling £15.5m incl existing + co-investor SIS Ventures |
2021-09-07 |
| EnteroBiotix–Thairm Bio: investment, 202109 financing round Series A totalling £15.5m incl lead investor Thairm Bio |
2021-09-07 |
| Owlstone–Horizons Ventures: investment, 202109 financing round Series D totalling $58m incl existing + lead investor Horizons Ventures |
2021-09-07 |
| Owlstone–SEVERAL: investment, 202109 financing round Series D $58m of Owlstone Medical led by existing investor Horizons Ventures |
2021-09-07 |
| ImmunOs Therapeutics–Akampion: public relations, 202109 service existent by Akampion |
2021-09-01 |
| Ascendis Pharma–SEVERAL: investment, 202108– public offering $400m + up to $60m of ADSs |
2021-08-31 |
| Tissium–Cathay Capital: investment, 202108 financing round Series C totalling €50m incl new + co-lead investor Cathay Health |
2021-08-31 |
| Tissium–SEVERAL: investment, 202108 financing round Series C €50m co-led by Cathay Health + Sofinnova Partners |
2021-08-31 |
| Tissium–Sofinnova: investment, 202108 financing round Series C totalling €50m incl existing + co-lead investor Sofinnova Partners |
2021-08-31 |
| NürnbergMesse–Messe Stuttgart: T4M trade show, 202108 acquistion of T4M event from Messe Stuttgart by MedtecLIVE GmbH |
2021-08-30 |
| Biognosys–ETH Zürich: LiP technology, 202108 collab developm + excl license from Institute of Systems Biology |
2021-08-27 |
| HealthCare Royalty–ADC Therapeutics: antibody-drug conjugates, 202108 acquisition $225m upfront + $100m milestones royalty rights to Zynlonta + Cami |
2021-08-26 |
| Afyren–SEVERAL: investment, 202108– IPO at Euronext Growth Paris registration document filed |
2021-08-25 |
| Cardior Pharmaceuticals–ABP (NL): investment, 202108 financing round Series B totalling €64m incl new + lead investor Inkef Capital |
2021-08-25 |
| Cardior Pharmaceuticals–BioMedPartners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BioMedPartners |
2021-08-25 |
| Cardior Pharmaceuticals–BMS: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BMS |
2021-08-25 |
| Cardior Pharmaceuticals–Fund+: investment, 202108 financing round Series B totalling €64m incl new + co-investor Fund+ |
2021-08-25 |
| Cardior Pharmaceuticals–Germany (govt): investment, 202108 financing round Series B totalling €64m incl new + co-investor Coparion |
2021-08-25 |
| Cardior Pharmaceuticals–Hadean Ventures: investment, 202108 financing round Series B totalling €64m incl new + co-investor Hadean Ventures |
2021-08-25 |
| Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 202108 financing round Series B totalling €64m incl existing + co-investor HTGF |
2021-08-25 |
| Cardior Pharmaceuticals–Life Sciences Partners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor LSP |
2021-08-25 |
| Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital |
2021-08-25 |
| Cardior Pharmaceuticals–Sunstone Life Science: investment, 202108 financing round Series B totalling €64m incl new + co-investor Sunstone |
2021-08-25 |
| Cardior Pharmaceuticals–Trophic Communications: public relations, 202108 service existent by Trophic Communications |
2021-08-25 |
| FarmInsect–5x Ventures: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor 5x Ventures |
2021-08-17 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
